Choosing Appropriate Estimands in Clinical Trials

被引:0
|
作者
Ann-Kristin Leuchs
Jörg Zinserling
Andreas Brandt
Dorothee Wirtz
Norbert Benda
机构
[1] Federal Institute for Drugs and Medical Devices (BfArM),
关键词
clinical trials; estimands; efficacy; effectiveness; nonadherence; missing data;
D O I
暂无
中图分类号
学科分类号
摘要
Lack of adherence to study protocol and missing data are often unavoidable in clinical trials, and both increase the need to differentiate between the ideal treatment effect if the medication is taken as directed and the treatment effect in presence of the actual adherence pattern. In this regard, estimands have become the focus of attention. An estimand is simply that which is being estimated. In the context of treatment benefit, an estimand may address either efficacy or effectiveness aspects. Defining the estimand of interest is an essential step to take before deciding on trial design and primary analysis. The choice of estimand has consequences for various other factors to be considered during any clinical trial’s planning phase. This study presents a process chart including all aspects to consider during planning. After deciding on the primary estimand, the trial design should be specified, followed by the primary analysis. Both should appropriately address the chosen estimand. Finally, sensitivity analyses should be taken into account. Provided are suggestions for all the planning steps involved, especially on choosing between efficacy and effectiveness, and relevant examples from clinical practice to illustrate them. It is recommended that one bear in mind the process chart during planning of any clinical trial and give reasonable justification for each decision in the study protocol.
引用
下载
收藏
页码:584 / 592
页数:8
相关论文
共 50 条
  • [31] Estimands: bringing clarity and focus to research questions in clinical trials
    Clark, Timothy Peter
    Kahan, Brennan C.
    Phillips, Alan
    White, Ian
    Carpenter, James R.
    BMJ OPEN, 2022, 12 (01):
  • [32] Response to comments on 'sensitivity of estimands in clinical trials with imperfect compliance'
    Chen, Heng
    Heitjan, Daniel F.
    INTERNATIONAL JOURNAL OF BIOSTATISTICS, 2024,
  • [33] Estimands for overall survival in clinical trials with treatment switching in oncology
    Manitz, Juliane
    Kan-Dobrosky, Natalia
    Buchner, Hannes
    Casadebaig, Marie-Laure
    Degtyarev, Evgeny
    Dey, Jyotirmoy
    Haddad, Vincent
    Jie, Fei
    Martin, Emily
    Mo, Mindy
    Rufibach, Kaspar
    Shentu, Yue
    Stalbovskaya, Viktoriya
    Tang, Rui
    Yung, Godwin
    Zhou, Jiangxiu
    PHARMACEUTICAL STATISTICS, 2022, 21 (01) : 150 - 162
  • [34] Translating questions to estimands in randomized clinical trials with intercurrent events
    Stensrud, Mats J.
    Dukes, Oliver
    STATISTICS IN MEDICINE, 2022, 41 (16) : 3211 - 3228
  • [35] Antiplatelet therapy in ischemic stroke: Variability in clinical trials and its impact on choosing the appropriate therapy
    Biller, Jose
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 284 (1-2) : 1 - 9
  • [36] Why estimands are needed to define treatment effects in clinical trials
    Keene, Oliver N.
    Lynggaard, Helle
    Englert, Stefan
    Lanius, Vivian
    Wright, David
    BMC MEDICINE, 2023, 21 (01)
  • [37] Estimands in hematologic oncology trials
    Sun, Steven
    Weber, Hans-Jochen
    Butler, Emily
    Rufibach, Kaspar
    Roychoudhury, Satrajit
    PHARMACEUTICAL STATISTICS, 2021, 20 (04) : 793 - 805
  • [38] The potential of the estimands framework for clinical pharmacology trials: Some discussion points
    Ring, Arne
    Wolfsegger, Martin J.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (07) : 1240 - 1247
  • [39] Reflections on estimands for patient-reported outcomes in cancer clinical trials
    Lawrance, Rachael
    Skaltsa, Konstantina
    Regnault, Antoine
    Floden, Lysbeth
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2023,
  • [40] Comments on "sensitivity of estimands in clinical trials with imperfect compliance" by Chen and Heitjan
    Baker, Stuart G.
    Lindeman, Karen S.
    INTERNATIONAL JOURNAL OF BIOSTATISTICS, 2024,